Serum neurofilament light chain as a biomarker of disease control in multiple sclerosis: a real-world cross-sectional analysis of therapeutic regimens
EID regimens were not associated with increased sNfL levels, suggesting that they may effectively limit neuroaxonal damage. Larger studies that assess the added value sNfL monitoring for safely personalizing treatment intervals in PwMS with initially active disease are needed.
Authors
- Wibke Johannis (ORCID: https://orcid.org/0000-0002-2886-7306)
- Gereon R. Fink (ORCID: https://orcid.org/0000-0002-8230-1856)
- Agni Konitsioti (ORCID: https://orcid.org/0000-0002-7296-4349)
- Finja Schweitzer (ORCID: https://orcid.org/0000-0003-0707-0485)
- Stefan Bittner (ORCID: https://orcid.org/0000-0003-2179-3655)
- Michael Schroeter (ORCID: https://orcid.org/0000-0001-8441-4793)
- Falk Steffen (ORCID: https://orcid.org/0000-0003-3708-8600)
- Clemens Warnke (ORCID: https://orcid.org/0000-0002-3510-9255)
Institutions
- Philipps University of Marburg (DE)
- Forschungszentrum Jülich (DE)
- University of Cologne (DE)
- Johannes Gutenberg University Mainz (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- University Hospital Cologne (DE)
Publication Details
- Journal
- Journal of Neurology
- Published
- 2025-12-19
- DOI
- https://doi.org/10.1007/s00415-025-13573-4
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00